Armada Acquisition Corp. III (AACI): Insider Trading, Congress Trades & Research | Tormere
AACI
$10.10-0.10%
Armada Acquisition Corp. III
Market Cap
—
Sector
—
Industry
Blank Checks
Beta (raw)
—
Insufficient price history
P/E (TTM)
—
Price / TTM diluted EPS
P/S (TTM)
—
Mkt cap / TTM revenue
P/B
—
Mkt cap / shareholders' equity
EV/EBITDA (TTM)
—
EV / TTM EBITDA
Loading…
Financial Statements
USD thousands
Q4 FY2025
Dec 31, 2025
Q1 FY2026
Mar 31, 2026
Q2 FY2026
Jun 30, 2026
Operating income
(373)
(308)
Net income
(53)
423
1,967
Weighted avg. shares (basic)
7,717
Weighted avg. shares (diluted)
7,717
Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source
Informational purposes only, not investment advice.
Armada Acquisition Corp. III (AACI)
tormere.com/research/AACI · generated 2026-11-07
$10.10
-0.10%
General Information
Price$10.10
Change-0.10%
Market Cap—
Sector—
IndustryBlank Checks
ExchangeNasdaq
Beta (raw, monthly vs SPY)—
Signals
Insider Velocity—
Congress Trades (90d)—
Short Volume
0% of daily vol
Conviction Score—
Price Chart (1 Year)
Recent News
Armada III to Combine With Brains in $750 Million Enterprise-Value Deal — TradingView · 2026-11-05
Share-price targets govern 14.7M earnout shares in Armada III (AACI)'s proposed Brains merger. — Stock Titan · 2026-11-05
Armada Acquisition Corp. III and Brains Bioceutical Corp. Announce Business Combination to Advance a Global Life Sciences and Pharmaceutical Innovation Platform — Yahoo · 2026-11-05
A proposed deal could take Brains Bioceutical public, valuing it at about $750 million. — Stock Titan · 2026-11-05
Armada Acquisition Corp. III And Brains Bioceutical Agree To Business Combination; Deal Values Brains Bioceutical At Implied Pre-Money Equity Value Of ~$750M — Benzinga · 2026-11-05
Tormere — informational purposes only, not investment advice.